When COVID-19 Presses Your Company To Make An R&D Pivot
Source: Life Science Leader
Rob Wright, chief editor of Life Science Leader, recently conducted a COVID-19 leadership roundtable with five biopharmaceutical CEOs via Zoom (view in full here). In this portion, Rachel Leheny, Ph.D., CEO of CalciMedica, discusses how her company, which had been studying an investigational compound (CM4620-IE) for patients with acute pancreatitis, pivoted and gained FDA approval to investigate if the compound could help patients suffering from COVID-19.
This website uses cookies to ensure you get the best experience on our website. Learn more